Pyxis Oncology, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for PYXS, updated each market day.
PYXS AI Sentiment
AI sees no strong directional signal for Pyxis Oncology, Inc. Common Stock stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Pyxis Oncology, Inc. Common Stock
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.
Sector
Exchange
Market Cap
$101,158,306
Cap Tier
Employees
56
Headquarters
BOSTON, MA
Listed Since
Oct. 8, 2021
Website
PYXS Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
PYXS Volatility
Pyxis Oncology, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
